Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jul 5, 2024 (Full proposal)

Later deadlines: Sep 5, 2024 (Letter of inquiry), Oct 5, 2024 (Full proposal), Oct 5, 2024 (Letter of inquiry), Nov 5, 2024 (Full proposal), Jan 5, 2025 (Letter of inquiry), Feb 5, 2025 (Full proposal), Feb 5, 2025 (Letter of inquiry), Mar 5, 2025 (Full proposal), May 5, 2025 (Letter of inquiry), Jun 5, 2025 (Full proposal), Jun 5, 2025 (Letter of inquiry), Jun 5, 2025 (Letter of inquiry), Jul 5, 2025 (Full proposal), Sep 5, 2025 (Letter of inquiry), Oct 5, 2025 (Full proposal), Oct 5, 2025 (Letter of inquiry), Nov 5, 2025 (Full proposal), Jan 5, 2026 (Letter of inquiry), Feb 5, 2026 (Full proposal), Feb 5, 2026 (Letter of inquiry), Mar 5, 2026 (Full proposal), May 5, 2026 (Letter of inquiry), Jun 5, 2026 (Full proposal), Jul 5, 2026 (Full proposal), Sep 5, 2026 (Letter of inquiry), Oct 5, 2026 (Full proposal), Oct 5, 2026 (Letter of inquiry), Nov 5, 2026 (Full proposal)

Grant amount: Unspecified amount

Fields of work: Cancer/Oncology Obesity

Applicant type: Nonprofit, Government Entity, Indigenous Group, For-Profit Business

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: The following deadlines apply to Standard grant applications (due by 5:00 pm local time of applicant organization): 

  • February 5, 2024
  • June 5, 2024
  • October 5, 2024
  • February 5, 2025
  • June 5 , 2025
  • October 5, 2025
  • February 5, 2026
  • June 5, 2026
  • October 5, 2026
The following deadlines apply to Renewal/Resubmission/Revision grant applications (due by 5:00 pm local time of applicant organization): 

  • March 5, 2024
  • July 5, 2024
  • November 5, 2024
  • March 5, 2025
  • July 5 , 2025
  • November 5, 2025
  • March 5, 2026
  • July 5, 2026
  • November 5, 2026
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

Your history with this funder
0
SAVED OPPORTUNITIES
No saved opportunities from this funder yet
FUNDER NOTES
Save this opportunity to add notes...
CONTACTS
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Find funders like US Dept. of Health & Human Services: National Institutes of Health (NIH)

See funders proven to support nonprofits like yours.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed August 25, 2023 and last updated August 24, 2023